Results 31 to 40 of about 30,003 (287)
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience? [PDF]
Drugs, 2021 Over time, clinicians have become increasingly comfortable embracing the prescription of biosimilars-highly similar versions of innovator or reference biological agents-for their patients with inflammatory diseases. Although a switch from a reference product to a licensed biosimilar version (or vice versa) is a medical decision robustly supported by ...
Mysler, Eduardo +7 more
openaire +3 more sources
Frontiers in Pharmacology, 2023 Background: Factors like the number of biosimilar competitors and competitive pricing strategies from originator companies may influence price competition and biosimilar uptake.Objective: The aim of this study was to analyze multiple facets of biosimilar
Elif Car +5 more
doaj +1 more source
Biosimilar infliximab introduction into the gastro-enterology care pathway in a large acute Irish teaching hospital: a story behind the evidence [PDF]
, 2018 Background and aim: Biosimilar medicines are not considered exact replicas of originator biological medicines. As a result, prescribers can be hesitant to introduce such medicines into the clinical setting until evidence surfaces confirming their safety ...
Byrne, Stephen +5 more
core +1 more source
, 2016 Rheumatoid arthritis is a chronic inflammatory joint disease, which can cause cartilage and bone damage as well as disability. Early diagnosis is key to optimal therapeutic success, particularly in patients with well-characterised risk factors for poor ...
Aletaha, Daniel +2 more
core +1 more source
Pharmacological Research, 2019 Biotechnologicals are an invaluable resource in the treatment of patients with inflammatory rheumatic diseases (IRD) non-responsive or intolerant to conventional therapies. However, they are the main driver for increase in direct costs and represent a significant economic burden to healthcare systems worldwide.
Araújo, Filipe C. +2 more
openaire +3 more sources
Generic and biosimilar medicines: quid?
Farmeconomia: Health Economics and Therapeutic Pathways, 2012 Once intellectual property protection, data and marketing exclusivity of reference medicines have expired, generic medicines and biosimilar medicines can enter the off-patent market.
Steven Simoens
doaj +1 more source
Adalimumab Originator vs. Biosimilar in Hidradenitis Suppurativa: A Multicentric Retrospective Study
Biomedicines, 2022 This study aimed to compare adalimumab originator vs. biosimilar in HS patients, and to evaluate the effect of a switch to a biosimilar, or a switch back to the originator, in terms of treatment ineffectiveness.
Martina Burlando +22 more
doaj +1 more source
Economic aspects of biosimilar competition in Hungary — The treatment of rheumatic disorders [PDF]
, 2017 Biologicals are the fastest growing segment of the global pharmaceutical market, reaching 199 billion USD sales per year with 9.8% 10-year compound annual growth rate (CAGR).
Zrubka, Zsombor
core +1 more source
Regulatory Science Ireland: bridging the information gap on biosimilar medicines [PDF]
, 2016 Regulatory Science Ireland (RSI) is a voluntary network of interested parties from academia, the Health Products Regulatory Authority (HPRA), pharmaceutical and medical device industries and government agencies.
Barry, Sean P. +6 more
core +1 more source
Indian Journal of Ophthalmology, 2021 Purpose: The aim of this study was to present the outcomes of the 2018 and 2020 Vitreo-retinal Society of India (VRSI) biosimilars of anti-vascular endothelial growth factor (VEGF) (VIBE) surveys.
Jay U Sheth +6 more
doaj +1 more source